LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease | Biogen
Biogen and Eisai launched LEQEMBI® Pen, a subcutaneous formulation of lecanemab, in Japan for early Alzheimer’s patients. The autoinjector allows weekly at-home administration, reducing clinic visits and healthcare resource use. LEQEMBI Pen is priced at 27,141 JPY per pen under Japan’s National Health Insurance. Eisai leads development, while both companies co-commercialize the product.
How this was made
The 30-second read
Why it matters
The announcement introduces a new administration route that could broaden patient access and drive sales growth in Japan.
Market read
First launch of a subcutaneous Alzheimer’s therapy in Japan, potentially boosting both companies' revenue outlooks.
What to watch
Pricing at ¥27,141 per pen and reimbursement decisions could limit market penetration.
Background
Biogen and Eisai issued a joint press release announcing the Japanese launch of the LEQEMBI® Pen, a subcutaneous autoinjector for early Alzheimer’s disease.
Ticker impact
Biogen announced the launch of the subcutaneous LEQEMBI® Pen in Japan, the first new administration route for its Alzheimer’s drug.
likely upward pressure as investors price in additional sales potential
First‑time launch in a major market, adds a weekly self‑admin option, and may boost revenue outlook.
Market effects
Expands the Alzheimer’s therapeutic market with a self‑admin option, may prompt competitors to consider similar formulations.
Adds a novel Alzheimer’s treatment route in Japan, potentially increasing local biotech activity.
Highlights a trend toward patient‑friendly delivery methods for biologics worldwide.
Counterpoint
If uptake is slow due to safety concerns or reimbursement hurdles, the launch may not translate into revenue.
Key entities
- CompanyBiogen Inc.
US biotech developer of lecanemab.
- CompanyEisai Co., Ltd.
Japanese partner and co‑commercializer of lecanemab.
.webp&w=2048&q=75)
